These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 9020426

  • 1. Antiallergic activity of topical lodoxamide on in vivo and in vitro models.
    Ciprandi G, Buscaglia S, Catrullo A, Paolieri F, Riccio AM, Fiorino N, Canonica GW.
    Allergy; 1996 Dec; 51(12):946-51. PubMed ID: 9020426
    [Abstract] [Full Text] [Related]

  • 2. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro.
    Buscaglia S, Paolieri F, Catrullo A, Fiorino N, Riccio AM, Pesce G, Montagna P, Bagnasco M, Ciprandi G, Canonica GW.
    Clin Exp Allergy; 1996 Oct; 26(10):1188-96. PubMed ID: 8911706
    [Abstract] [Full Text] [Related]

  • 3. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
    Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW.
    Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
    [Abstract] [Full Text] [Related]

  • 4. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge.
    Ciprandi G, Buscaglia S, Pesce G, Passalacqua G, Rihoux JP, Bagnasco M, Canonica GW.
    J Allergy Clin Immunol; 1995 Feb; 95(2):612-21. PubMed ID: 7531732
    [Abstract] [Full Text] [Related]

  • 5. Lodoxamide treatment of allergic conjunctivitis.
    Cerqueti PM, Ricca V, Tosca MA, Buscaglia S, Ciprandi G.
    Int Arch Allergy Immunol; 1994 Oct; 105(2):185-9. PubMed ID: 7920019
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
    Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A, Bucci MG.
    Ophthalmology; 1997 May; 104(5):849-53. PubMed ID: 9160033
    [Abstract] [Full Text] [Related]

  • 7. Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen.
    Purello D'Ambrosio F, Gangemi S, Ricciardi L, Cuzzocrea S, Di Lorenzo G.
    Allergol Immunopathol (Madr); 1997 May; 25(5):233-7. PubMed ID: 9395007
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis.
    Oguz H, Bitiren M, Aslan OS, Ozardali I.
    Acta Med Okayama; 1999 Jun; 53(3):123-6. PubMed ID: 10410789
    [Abstract] [Full Text] [Related]

  • 9. A clinicopathological analysis of the efficacy of lodoxamide 0.1% eye drops on the conjunctiva of patients with vernal keratoconjunctivitis seen at Guinness Eye Centre, Lagos University Teaching Hospital.
    Adefule-Ositelu AO, Onakoya AO, Olasimbo OO, Adefule AK.
    Niger Postgrad Med J; 2006 Mar; 13(1):35-40. PubMed ID: 16633377
    [Abstract] [Full Text] [Related]

  • 10. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis.
    Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E, Lodoxamide Study Group.
    Eur J Ophthalmol; 2001 Mar; 11(2):120-5. PubMed ID: 11456011
    [Abstract] [Full Text] [Related]

  • 11. Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.
    Yanni JM, Weimer LK, Glaser RL, Lang LS, Robertson SM, Spellman JM.
    Int Arch Allergy Immunol; 1993 Mar; 101(1):102-6. PubMed ID: 7684628
    [Abstract] [Full Text] [Related]

  • 12. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
    Richard C, Trinquand C, Bloch-Michel E.
    Eur J Ophthalmol; 1998 Mar; 8(4):207-16. PubMed ID: 9891891
    [Abstract] [Full Text] [Related]

  • 13. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
    Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L, Di Giovanni A, Lecorvec M.
    Br J Ophthalmol; 1998 Oct; 82(10):1135-8. PubMed ID: 9924299
    [Abstract] [Full Text] [Related]

  • 14. Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions.
    Ciprandi G, Cosentino C, Milanese M, Tosca MA.
    Ann Allergy Asthma Immunol; 2003 Apr; 90(4):434-8. PubMed ID: 12722967
    [Abstract] [Full Text] [Related]

  • 15. [Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases].
    Dekaris I, Gabrić N, Lazić R, Bosnar D, Cima I, Stipić A.
    Acta Med Croatica; 2002 Apr; 56(3):93-8. PubMed ID: 12630339
    [Abstract] [Full Text] [Related]

  • 16. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide.
    Leonardi AA, Smith LM, Fregona IA, Salmaso M, Secchi AG.
    Eur J Ophthalmol; 1996 Apr; 6(2):106-12. PubMed ID: 8823580
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of lodoxamide 0.1% vs cromolyn sodium 4% in patients with vernal keratoconjunctivitis.
    Caldwell DR, Verin P, Hartwich-Young R, Meyer SM, Drake MM.
    Am J Ophthalmol; 1992 Jun 15; 113(6):632-7. PubMed ID: 1598953
    [Abstract] [Full Text] [Related]

  • 18. Deflazacort protects against late-phase but not early-phase reactions induced by the allergen-specific conjunctival provocation test.
    Ciprandi G, Buscaglia S, Pesce GP, Iudice A, Bagnasco M, Canonica GW.
    Allergy; 1993 Aug 15; 48(6):421-30. PubMed ID: 7902021
    [Abstract] [Full Text] [Related]

  • 19. Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study.
    Mann JS, Clement P, Sheridan AQ, Soryal I, Fairfax AJ, Holgate ST.
    J Allergy Clin Immunol; 1985 Jul 15; 76(1):83-90. PubMed ID: 4008815
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis.
    Gündüz K, Uçakhan O, Budak K, Eryilmaz T, Ozkan M.
    Ophthalmic Res; 1996 Jul 15; 28(2):80-7. PubMed ID: 8792357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.